Introduction
The launch of five novel orally administered disease-modifiers is set to
revolutionize the multiple sclerosis (MS) market, which will more than double
in value across the seven major markets from 2006 to reach $10.7 billion in
2016.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
multiple sclerosis
- Overview of drugs in late- and early-stage clinical development; with
analysis of key companies involved in the R&D pipeline
- Detailed profiles of key compounds in development for use in multiple
sclerosis, with forecasts of drug revenues to 2016
- Discussion of Biogen Idec' s and Teva' s strategies and insight from key
industry opinion leaders
Report Highlights
There is a significant need for a MS treatment with superior efficacy to
current therapies with a less invasive and time-consuming route of
administration. Novartis' s oral Fingolimod (FTY720) goes some way to meet
these needs and represents the most highly anticipated pipeline drug since the
initial launch of Tysabri in 2004.
Amid an increasingly competitive first-line therapy market, Datamonitor
believes prospective players can gain competitive edge (and healthcare payer
acceptance) by defining clear clinical differentiators in their trials.
Head-to-head studies with a suitable comparator or showing benefit of add-on
therapy represent two possible strategies.
Biogen Idec' s Rituxan (rituximab) and BioMS' s MBP-8298 are targeting the
prevalent yet largely underserved primary progressive MS (PPMS) and secondary
progressive MS (SPMS) indications. Datamonitor predicts that if Rituxan and
MBP-8298 launch, then strong uptake can be expected.
Reasons to Purchase
- Understand unmet needs in the multiple sclerosis market based on key
opinion leader comments
- Benchmark key late-stage disease-modifying multiple sclerosis compounds
against current market leaders
- Assess the global (US, Japan, five major EU) sales forecasts of key
late-stage pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
